Aquamid Reconstruction for Osteoarthritis of the Knee

A

A2 Reumatologi Og Idrætsmedicin

Status

Unknown

Conditions

Osteoarthritis, Knee

Treatments

Device: Aquamid Reconstruction

Study type

Interventional

Funder types

Other

Identifiers

NCT03067090
A2-001

Details and patient eligibility

About

Osteoarthritis (OA) causes degradation and deformities of joints, including knees, hips, hands, and feet. Approximately more than 55% of populations above 45 years and more than 70% of population above 70 years will develop OA in at least one joint. The symptoms are dominated by pain but also stiffness and swelling occur. There is currently no cure for OA, and the ultimate treatment is joint replacement surgery. However, there is an unmet need to identify other treatment options that may delay or avoid surgery. Aquamid Reconstruction (AR) is a polyacrylamide hydrogel (PAAG) which is a non-degradable, highly visco-elastic synthetic gel, which is atoxic with durable effect and tissue-compatibility and well tolerated by mammal tissue by allowing in vivo vessel and fibrous in-growth. Experimental studies supported by histopathological observations have shown that AR exerts its effect via integration over time within the soft tissues, through a combination of vessel in-growth and molecular water exchange. Intra-articular injection of AR is expected to provide permanent pain relief and improve the functional ability through a cushioning or padding effect on the joint and thereby reduce symptoms and improve patients' quality of life. The purpose of this study is to obtain information of the safety and effectiveness of AR in patients with OA of the knee.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age > 18 years
  • WOMAC pain score >/= 5
  • Kellgren and Lawrence radiographic scoring >/= 1
  • Signed informed consent form

Exclusion criteria

  • Other diseases affecting the joints such as rheumatoid arthritis
  • Actual or recurrent infections requiring intravenous antibiotic treatment within the last 30 days or oral antibiotic treatment within the last 14 days before inclusion
  • Less than 12 weeks since injection of HA or corticosteroids in study-knee joint before treatment
  • Pregnancy or lactation
  • Not able to comply with the requirements of the study
  • Previous alloplasty

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

50 participants in 1 patient group

Intra-articular Aquamid Reconstruction
Experimental group
Description:
Intra-articular injection of 3 ml aquamid reconstruction (AR) to the knee. A second injection of 3 ml will take place after 1 month (+/- 2 weeks).
Treatment:
Device: Aquamid Reconstruction

Trial contacts and locations

1

Loading...

Central trial contact

Andreas Hartkopp, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems